查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1404812

胜肽療法市場規模、佔有率、趨勢分析報告：按應用、類型、製造商、給藥途徑、合成技術、地區、細分市場預測，2024-2030

Peptide Therapeutics Market Size, Share & Trends Analysis Report By Application, By Type, By Type of Manufacturer, By Route of Administration, By Synthesis Technology, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 110 Pages | 商品交期: 2-10個工作天內

價格

胜肽治療市場成長與趨勢：

Grand View Research, Inc. 的最新報告顯示，到 2030 年，全球胜肽治療市場規模預計將達到 664.1 億美元。

預計2024年至2030年複合年成長率為6.1%。對於癌症和其他與文明病的治療，對高效、快速、副作用較少的藥物的需求不斷成長，預計這將推動市場成長。由於治療方法，預計癌症發病率的上升將推動市場發展。此外，不斷增加的老年人口預計將透過誘發癌症和糖尿病等目標疾病的發病率來擴大消費群，這預計將推動對胜肽治療藥物的需求。

根據全球癌症研究組織（GLOBOCAN 2020）的報告，2020年全球將有19,292,789人新診斷出癌症，9,958,133人將死於癌症。此外，全球 5 年癌症盛行率預計為 50,550,287 人。到 2040 年，全球新增癌症患者人數預計將達到 28,887,940 人。因此，全球癌症的高發生率將在預測期內對胜肽療法的開發發揮重要作用。此外，醫療保健提供者和患者對化療和放射線治療不良反應的認知不斷提高，是影響人們更加重視勝胜肽藥物等替代療法的一個主要因素。

在預測期內，胜肽製造流程的技術進步正在推動市場發展。製造商和供應商致力於採用新技術，以更少的時間和資本投資生產高效的藥物分子。精製和自動化製程的改進以及廢棄物產生量的減少是進一步推動市場成長的因素。例如，安進公司於 2022 年 3 月宣布，將在北卡羅來納州霍利斯普林斯正式開設一家最先進的生物製造工廠。該設施計劃於 2025 年開業，將有助於適應安進治療癌症和心臟病等嚴重疾病的藥物的成長。

COVID-19大流行加速了癌症治療領域的發展，包括延遲診斷、治療性介入以及阻礙專注於開發具有成本效益的癌症治療頻譜的臨床試驗。預計情況會是這樣，用於癌症治療的胜肽療法正在2020年《自然癌症》雜誌上發表的一篇研究論文稱，也不例外。截至2020年5月，已有21種用於治療COVID-19的胜肽，其中包括15種用於治療急性呼吸窘迫症候群（ARDS）和嚴重急性呼吸道感染疾病引起的其他呼吸系統疾病的合成勝胜肽類藥物。然而，胜肽療法在癌症、代謝性疾病和其他疾病中的實用化目前受到藥物短缺、操作問題以及涉及非 COVID-19 療法的臨床試驗進展緩慢的阻礙。

例如，2022年5月，EVER Pharma宣布硼替佐米獲得歐盟範圍內核准用於治療症狀性骨髓瘤和套細胞淋巴瘤1。核准諾華的Jakavi後類固醇療法治療慢性移植物抗宿主疾病。 Jakavi 將成為歐洲首個廣泛用於類固醇抗藥性移植物抗宿主疾病患者的 JAK1/2 抑制劑。 2021 年 9 月，Nimble Therapeutics 和 Incyte 開始策略合作，以發現更多新型胜肽療法。

胜肽治療市場報告亮點

  • 以應用程式來看，由於對替代治療方法的需求超過傳統治療方法，癌症在 2023 年佔據第二大銷售佔有率。胜肽被用作癌症治療中的潛在治療劑。
  • 在學名藥領域，由於重磅勝胜肽的專利到期以及政府積極推出學名藥相關舉措，銷售額預計將增加。
  • 由於複雜的程序要求和外包偏好的變化有助於降低製造成本，預計外包製造業在預測期內將以最快的複合年成長率成長。
  • 從合成技術來看，混合技術預計在預測期內成長最快。與此技術相關的優勢，例如節省時間以及固相和液相胜肽合成的易用性，是推動成長的關鍵因素。
  • 由於對基因組學和蛋白​​質組學產品的高度認知、已建立的舉措基礎設施以及不斷增加的資金籌措舉措，北美在 2023 年佔據了最大的銷售佔有率。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章胜肽治療市場變數、趨勢和範圍

  • 胜肽治療市場的系統展望
    • 母市場展望
    • 輔助設備市場
  • 市場動態
    • 市場促進因素分析
    • 市場抑制因素分析
  • 胜肽治療市場分析工具
    • 波特五力分析
    • PESTLE分析

第 4 章胜肽治療市場 - 按應用細分分析，2018-2030

  • 胜肽治療市場：應用變異分析
  • 按用途
    • 癌症
    • 代謝紊亂
    • 心血管疾病
    • 呼吸系統疾病
    • 胃腸道疾病
    • 感染疾病
    • 疼痛
    • 皮膚病
    • 神經系統疾病
    • 腎臟疾病
    • 其他

第5章胜肽治療市場：按類型細分分析，2018-2030

  • 胜肽治療市場：類型變異分析
  • 按類型
    • 非專利的
    • 創新的

第 6 章胜肽治療市場：2018-2030 年按製造商類型分類的細分分析

  • 胜肽治療市場：按製造商類型分類的波動分析
  • 按製造商類型
    • 公司內部
    • 委託

第 7 章胜肽治療市場：依給藥途徑細分分析，2018-2030

  • 胜肽治療市場：給藥變化分析
  • 依給藥途徑
    • 腸外途徑
    • 口服
    • 肺
    • 黏膜
    • 其他

第 8 章胜肽治療市場 - 按合成技術細分分析，2018-2030 年

  • 胜肽治療藥物市場：合成技術波動分析
  • 透過合成技術
    • 固相勝胜肽合成（SPPS）
    • 液相胜肽合成（LPPS）
    • 混合技術

第9章胜肽治療藥物市場：按應用、類型、製造商類型、給藥途徑和合成技術進行的區域估計和趨勢分析

  • 胜肽治療市場：區域展望
  • 北美洲
    • 2018-2030年北美胜肽治療市場估計與預測
    • 美國
    • 加拿大
  • 歐洲
    • 2018-2030 年歐洲胜肽治療市場估計與預測
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 2018-2030年亞太地區胜肽治療市場估計與預測
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 泰國
    • 韓國
    • 2018-2030 年其他亞太勝胜肽治療市場估計與預測
  • 拉丁美洲
    • 2018-2030 年拉丁美洲胜肽治療市場估計與預測
    • 巴西
    • 墨西哥
    • 阿根廷
    • 2018-2030 年其他拉丁美洲胜肽治療市場估計與預測
  • 中東/非洲
    • 2018-2030年中東和非洲胜肽治療市場估計和預測
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第10章競爭形勢

  • 公司分類
  • 策略規劃
    • 新產品發布
    • 合夥
    • 獲得
    • 合作
    • 資金籌措
  • 2023年主要企業市場佔有率分析
  • 公司簡介
    • Eli Lilly and Company
    • Pfizer Inc.
    • Amgen Inc.
    • Takeda Pharmaceutical Company Limited
    • Sanofi
    • AstraZeneca
    • Teva Pharmaceutical Industries Ltd.
    • F. Hoffmann-La Roche Ltd
    • Novartis AG
    • Novo Nordisk A/S
    • GlaxoSmithKline plc.
    • Ironwood Pharmaceuticals, Inc.
    • Radius Health, Inc.
    • Ipsen Pharma

第11章結論

Product Code: 978-1-68038-179-5

Peptide Therapeutics Market Growth & Trends:

The global peptide therapeutics market size is expected to reach USD 66.41 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to grow at a CAGR of 6.1% from 2024 to 2030. Increasing demand for efficient and rapid-acting therapeutics for the treatment of cancer and other lifestyle-associated disorders, which result in lesser adverse effects, is anticipated to propel market growth. The rising incidence of cancer calls for exploring and introducing other means of therapies and low-cost treatment alternatives is expected to drive the market. Moreover, the growing geriatric population is expected to widen the consumer base by triggering the incidence rate of target diseases such as cancer and diabetes, which is expected to drive the demand for peptide therapeutics.

As per the International Agency for Research on Cancer (GLOBOCAN 2020) report, there will be 19,292,789 new cancer cases diagnosed globally in 2020, with 9,958,133 cancer deaths. Furthermore, the five-year prevalence of cancer was projected to be 50,550,287 worldwide. The global number of new cases of cancer is projected to reach 28,887,940 by 2040. As a result, the higher incidence of cancers around the world is set to perform an important role in the development of peptide therapeutics over the forecast period. Besides that, increasing awareness among health care providers and patients about the negative effects of chemotherapy and/or radiation therapy is a primary factor influencing the increased emphasis on alternative therapeutics like peptide-based drugs.

Technological advancements in the peptide manufacturing process are driving the market during the forecast period. Manufacturers and suppliers are focusing on the adoption of novel technologies to manufacture efficient drug molecules with low time and capital investment. Improvement in purification and automation process and less generation of waste are additional factors contributing to the market growth. For instance, in March 2022, Amgen announced the official opening of its latest bio-manufacturing facility in Holly Springs, North Carolina. The facility, which is set to open in 2025, will help cope with the growth of Amgen's medicines, which treat serious diseases like cancer and heart disease.

The COVID-19 pandemic is anticipated to spur the spectrum of cancer care, which includes delayed diagnoses, therapeutic interventions, and the impeding of clinical trials focused on developing cost-effective therapeutics for cancer treatment, with peptide therapeutics for cancer treatment being no exception, as per a research article published in Nature Cancer, 2020. There have been 21 peptide drugs in therapies for the treatment of COVID-19 as of May 2020, such as 15 synthetic peptides for the therapies of acute respiratory distress syndrome (ARDS) as well as other respiratory illnesses induced by severe acute respiratory infection. However, current implementations of peptide therapeutics in oncological and metabolic disorders and other fields have been hampered by drug shortages, operational problems, and the slow progress of clinical trials involving non-COVID-19 therapeutics.

For instance, in May 2022, EVER Pharma announced that Bortezomib has received EU-wide approval for the treatment of individuals with symptomatic myeloma and mantle cell lymphoma1. In May 2022, The European Commission approved Novartis' Jakavi post-steroid therapy for acute and chronic graft-versus-host ailments. Jakavi will be the first JAK1/2 inhibitor widely available for patients in Europe with steroid-refractory graft-versus-host ailment. In September 2021, Nimble Therapeutics and Incyte entered into strategic collaborative research to discover additional new peptide therapies.

Peptide Therapeutics Market Report Highlights:

  • By application, cancer held the second-largest revenue share in 2023 owing to the increasing demand for alternative therapeutics over conventional treatment options. Peptides are being used as potential therapeutic agents in cancer treatment
  • The generic type segment is expected to showcase an upward shift due to the patent expiration of blockbuster peptides and supportive government initiatives pertaining to the introduction of the generic class
  • Outsourcing manufacturing segment is anticipated to grow at the fastest CAGR during the forecast period owing to the requirements of complex procedures and a shift in preference toward outsourcing, which helps in eliminating the cost of production
  • By synthesis technology, hybrid technology is expected to witness the fastest growth over the forecast period. Benefits associated with this technology such as time conservation and ease of usage for both solid- and liquid-phase peptide synthesis are the key factors affirming growth
  • North America held the largest share in terms of revenue in 2023 owing to a higher level of awareness pertaining to genomics and proteomics products, well-established R&D infrastructure, and rising funding initiatives

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation
    • 1.1.1 Regional Scope
    • 1.1.2 Market Definitions
    • 1.1.3 Estimates and Forecast Timeline
  • 1.2 Objectives
    • 1.2.1 Objective - 1
    • 1.2.2 Objective - 2
    • 1.2.3 Objective - 3
  • 1.3 Research Methodology
  • 1.4 Information Procurement
    • 1.4.1 Purchased Database
    • 1.4.2 GVR's Internal Database
    • 1.4.3 Secondary Sources
    • 1.4.4 Primary Research
    • 1.4.5 Details of Primary Research
  • 1.5 Information or Data Analysis
    • 1.5.1 Data Analysis Models
  • 1.6 Market Formulation & Validation
  • 1.7 Model Details
    • 1.7.1 Commodity Flow Analysis
      • 1.7.1.1 Approach 1: Commodity Flow Approach
      • 1.7.1.2 Approach 2: Country-wise market estimation using bottom-up approach
  • 1.8 List of Secondary Sources
  • 1.9 List of Abbreviations

Chapter 2 Executive Summary

  • 2.1 Market Snapshot
  • 2.2 Application Segment Snapshot
  • 2.3 Type and Type of Manufacturers Segment Snapshot
  • 2.4 Route of Administration and Synthesis Technology Segment Snapshot
  • 2.5 Competitive Landscape Snapshot

Chapter 3 Peptide Therapeutics Market Variables, Trends, and Scope

  • 3.1 Peptide Therapeutics Market Lineage Outlook
    • 3.1.1 Parent Market Outlook
    • 3.1.2 Ancillary Market
  • 3.2 Market Dynamics
    • 3.2.1 Market Driver Analysis
      • 3.2.1.1 Increasing Incidence of Cancer
      • 3.2.1.1.1 Cancer Incidence Data
      • 3.2.1.2 Rising Prevalence of Metabolic Disorders
      • 3.2.1.3 Presence of Strong Product Pipeline
      • 3.2.1.4 Technological Advancements
    • 3.2.2 Market Restraint Analysis
      • 3.2.2.1 Increasing Complexity of Peptides
      • 3.2.2.2 High Cost of Manufacturing Equipment
  • 3.3 Peptide Therapeutics Market Analysis Tools
    • 3.3.1 Porter's Five Forces Analysis
    • 3.3.2 PESTLE Analysis

Chapter 4 Peptide Therapeutics Market - Segment Analysis, by Application, 2018 - 2030 (USD Million)

  • 4.1 Peptide Therapeutics Market: Application Movement Analysis
  • 4.2 Peptide Therapeutics Market Estimates & Forecast, By Application (USD Million)
    • 4.2.1 Cancer
    • 4.2.2 Metabolic Disorders
    • 4.2.3 Cardiovascular Disorders
    • 4.2.4 Respiratory Disorders
    • 4.2.5 Gastrointestinal Disorders
    • 4.2.6 Infectious Diseases
    • 4.2.7 Pain
    • 4.2.8 Dermatological Disorders
    • 4.2.9 Neurological Disorders
    • 4.2.10 Renal Disorders
    • 4.2.11 Others

Chapter 5 Peptide Therapeutics Market: Segment Analysis, by Type, 2018 - 2030 (USD Million)

  • 5.1 Peptide Therapeutics Market: Type Movement Analysis
  • 5.2 Peptide Therapeutics Market Estimates & Forecast, by Type (USD Million)
    • 5.2.1 Generic
    • 5.2.2 Innovative

Chapter 6 Peptide Therapeutics Market: Segment Analysis, By Type Of Manufacturers, 2018 - 2030 (USD Million)

  • 6.1 Peptide Therapeutics Market: Type of Manufacturers Movement Analysis
  • 6.2 Peptide Therapeutics Market Estimates & Forecast, by Type Of Manufacturers (USD Million)
    • 6.2.1 In-house
    • 6.2.2 Outsourced

Chapter 7 Peptide Therapeutics Market: Segment Analysis, by Route Of Administration, 2018 - 2030 (USD Million)

  • 7.1 Peptide Therapeutics Market: Route Of Administration Movement Analysis
  • 7.2 Peptide Therapeutics Market Estimates & Forecast, by Route Of Administration (USD Million)
    • 7.2.1 Parenteral Route
    • 7.2.2 Oral Route
    • 7.2.3 Pulmonary
    • 7.2.4 Mucosal
    • 7.2.5 Others

Chapter 8 Peptide Therapeutics Market - Segment Analysis, by Synthesis Technology, 2018 - 2030 (USD Million)

  • 8.1 Peptide Therapeutics Market: Synthesis Technology Movement Analysis
  • 8.2 Peptide Therapeutics Market Estimates & Forecast, By Synthesis Technology (USD Million)
    • 8.2.1 Solid Phase Peptide Synthesis (SPPS)
    • 8.2.2 Liquid Phase Peptide Synthesis (LPPS)
    • 8.2.3 Hybrid Technology

Chapter 9 Peptide Therapeutics Market: Regional Estimates and Trend Analysis by Application, Type, Type of Manufacturer, Route of Administration, and Synthesis Technology

  • 9.1 Peptide Therapeutics Market: Regional Outlook
  • 9.2 North America
    • 9.2.1 North America Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.2.2 U.S.
      • 9.2.2.1 Key Country Dynamics
      • 9.2.2.2 Target Disease Prevalence
      • 9.2.2.3 U.S. Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 9.2.2.4 Competitive/Market Scenario
      • 9.2.2.5 Regulatory Framework
      • 9.2.2.6 Reimbursement Scenario
    • 9.2.3 Canada
      • 9.2.3.1 Key Country Dynamics
      • 9.2.3.2 Target Disease Prevalence
      • 9.2.3.3 Canada Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 9.2.3.4 Competitive/Market Scenario
      • 9.2.3.5 Regulatory Framework
      • 9.2.3.6 Reimbursement Scenario
  • 9.3 Europe
    • 9.3.1 Europe Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.2 UK
      • 9.3.2.1 Key Country Dynamics
      • 9.3.2.2 Target Disease Prevalence
      • 9.3.2.3 UK Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 9.3.2.4 Competitive/Market Scenario
      • 9.3.2.5 Regulatory Framework
      • 9.3.2.6 Reimbursement Scenario
    • 9.3.3 Germany
      • 9.3.3.1 Key Country Dynamics
      • 9.3.3.2 Target Disease Prevalence
      • 9.3.3.3 Germany Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 9.3.3.4 Competitive/Market Scenario
      • 9.3.3.5 Regulatory Framework
      • 9.3.3.6 Reimbursement Scenario
    • 9.3.4 France
      • 9.3.4.1 Key Country Dynamics
      • 9.3.4.2 Target Disease Prevalence
      • 9.3.4.3 France Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 9.3.4.4 Competitive/Market Scenario
      • 9.3.4.5 Regulatory Framework
      • 9.3.4.6 Reimbursement Scenario
    • 9.3.5 Spain
      • 9.3.5.1 Key Country Dynamics
      • 9.3.5.2 Target Disease Prevalence
      • 9.3.5.3 Spain Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 9.3.5.4 Competitive/Market Scenario
      • 9.3.5.5 Regulatory Framework
      • 9.3.5.6 Reimbursement Scenario
    • 9.3.6 Italy
      • 9.3.6.1 Key Country Dynamics
      • 9.3.6.2 Target Disease Prevalence
      • 9.3.6.3 Italy Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 9.3.6.4 Competitive/Market Scenario
      • 9.3.6.5 Regulatory Framework
      • 9.3.6.6 Reimbursement Scenario
    • 9.3.7 Denmark
      • 9.3.7.1 Key Country Dynamics
      • 9.3.7.2 Target Disease Prevalence
      • 9.3.7.3 Denmark Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 9.3.7.4 Competitive/Market Scenario
      • 9.3.7.5 Regulatory Framework
      • 9.3.7.6 Reimbursement Scenario
    • 9.3.8 Sweden
      • 9.3.8.1 Key Country Dynamics
      • 9.3.8.2 Target Disease Prevalence
      • 9.3.8.3 Sweden Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 9.3.8.4 Competitive/Market Scenario
      • 9.3.8.5 Regulatory Framework
      • 9.3.8.6 Reimbursement Scenario
    • 9.3.9 Norway
      • 9.3.9.1 Key Country Dynamics
      • 9.3.9.2 Target Disease Prevalence
      • 9.3.9.3 Norway Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 9.3.9.4 Competitive/Market Scenario
      • 9.3.9.5 Regulatory Framework
      • 9.3.9.6 Reimbursement Scenario
      • 9.3.9.7 Rest of Europe Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.4 Asia Pacific
    • 9.4.1 Asia Pacific Peptide Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.4.2 Japan
      • 9.4.2.1 Key Country Dynamics
      • 9.4.2.2 Target Disease Prevalence
      • 9.4.2.3 Japan Peptide Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.4.2.4 Competitive/Market Scenario
      • 9.4.2.5 Regulatory Framework
      • 9.4.2.6 Reimbursement Scenario
    • 9.4.3 China
      • 9.4.3.1 Key Country Dynamics
      • 9.4.3.2 Target Disease Prevalence
      • 9.4.3.3 China Peptide Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.4.3.4 Competitive/Market Scenario
      • 9.4.3.5 Regulatory Framework
      • 9.4.3.6 Reimbursement Scenario
    • 9.4.4 India
      • 9.4.4.1 Key Country Dynamics
      • 9.4.4.2 Target Disease Prevalence
      • 9.4.4.3 India Peptide Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.4.4.4 Competitive/Market Scenario
      • 9.4.4.5 Regulatory Framework
      • 9.4.4.6 Reimbursement Scenario
    • 9.4.5 Australia
      • 9.4.5.1 Key Country Dynamics
      • 9.4.5.2 Target Disease Prevalence
      • 9.4.5.3 Australia Peptide Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.4.5.4 Competitive/Market Scenario
      • 9.4.5.5 Regulatory Framework
    • 9.4.6 Thailand
      • 9.4.6.1 Key Country Dynamics
      • 9.4.6.2 Thailand Peptide Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.4.6.3 Competitive/Market Scenario
      • 9.4.6.4 Regulatory Framework
      • 9.4.6.5 Reimbursement Scenario
    • 9.4.7 South Korea
      • 9.4.7.1 Key Country Dynamics
      • 9.4.7.2 South Korea Peptide Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.4.7.3 Competitive/Market Scenario
      • 9.4.7.4 Regulatory Framework
      • 9.4.7.5 Reimbursement Scenario
    • 9.4.8 Rest of Asia Pacific Peptide Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.5 Latin America
    • 9.5.1 Latin America Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.5.2 Brazil
      • 9.5.2.1 Key Country Dynamics
      • 9.5.2.2 Target Disease Prevalence
      • 9.5.2.3 Brazil Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 9.5.2.4 Competitive/Market Scenario
      • 9.5.2.5 Regulatory Framework
      • 9.5.2.6 Reimbursement Scenario
    • 9.5.3 Mexico
      • 9.5.3.1 Key Country Dynamics
      • 9.5.3.2 Target Disease Prevalence
      • 9.5.3.3 Mexico Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 9.5.3.4 Competitive/Market Scenario
      • 9.5.3.5 Regulatory Framework
      • 9.5.3.6 Reimbursement Scenario
    • 9.5.4 Argentina
      • 9.5.4.1 Key Country Dynamics
      • 9.5.4.2 Target Disease Prevalence
      • 9.5.4.3 Argentina Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 9.5.4.4 Competitive/Market Scenario
      • 9.5.4.5 Regulatory Framework
      • 9.5.4.6 Reimbursement Scenario
    • 9.5.5 Rest of Latin America Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.6 MEA
    • 9.6.1 MEA Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.6.2 South Africa
      • 9.6.2.1 Key Country Dynamics
      • 9.6.2.2 Target Disease Prevalence
      • 9.6.2.3 South Africa Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 9.6.2.4 Competitive/Market Scenario
      • 9.6.2.5 Regulatory Framework
      • 9.6.2.6 Reimbursement Scenario
    • 9.6.3 Saudi Arabia
      • 9.6.3.1 Key Country Dynamics
      • 9.6.3.2 Target Disease Prevalence
      • 9.6.3.3 Saudi Arabia Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 9.6.3.4 Competitive/Market Scenario
      • 9.6.3.5 Regulatory Framework
      • 9.6.3.6 Reimbursement Scenario
    • 9.6.4 UAE
      • 9.6.4.1 Key Country Dynamics
      • 9.6.4.2 Target Disease Prevalence
      • 9.6.4.3 UAE Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 9.6.4.4 Competitive/Market Scenario
      • 9.6.4.5 Regulatory Framework
      • 9.6.4.6 Reimbursement Scenario
    • 9.6.5 Kuwait
      • 9.6.5.1 Key Country Dynamics
      • 9.6.5.2 Target Disease Prevalence
      • 9.6.5.3 Kuwait Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 9.6.5.4 Competitive/Market Scenario
      • 9.6.5.5 Regulatory Framework
      • 9.6.5.6 Reimbursement Scenario
      • 9.6.5.7 Rest of MEA Peptide Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 10 Competitive Landscape

  • 10.1 Company Categorization
  • 10.2 Strategy Mapping
    • 10.2.1 New Product Launch
    • 10.2.2 Partnerships
    • 10.2.3 Acquisition
    • 10.2.4 Collaboration
    • 10.2.5 Funding
  • 10.3 Key Company Market Share Analysis, 2023
  • 10.4 Company Profiles
    • 10.4.1 Eli Lilly and Company
      • 10.4.1.1 Company overview
      • 10.4.1.2 Financial performance
      • 10.4.1.3 Product benchmarking
      • 10.4.1.4 Strategic initiatives
    • 10.4.2 Pfizer Inc.
      • 10.4.2.1 Company overview
      • 10.4.2.2 Financial performance
      • 10.4.2.3 Product benchmarking
      • 10.4.2.4 Strategic initiatives
    • 10.4.3 Amgen Inc.
      • 10.4.3.1 Company overview
      • 10.4.3.2 Financial performance
      • 10.4.3.3 Product benchmarking
      • 10.4.3.4 Strategic initiatives
    • 10.4.4 Takeda Pharmaceutical Company Limited
      • 10.4.4.1 Company overview
      • 10.4.4.2 Financial performance
      • 10.4.4.3 Product benchmarking
      • 10.4.4.4 Strategic initiatives
    • 10.4.5 Sanofi
      • 10.4.5.1 Company overview
      • 10.4.5.2 Financial performance
      • 10.4.5.3 Product benchmarking
      • 10.4.5.4 Strategic initiatives
    • 10.4.6 AstraZeneca
      • 10.4.6.1 Company overview
      • 10.4.6.2 Financial performance
      • 10.4.6.3 Product benchmarking
      • 10.4.6.4 Strategic initiatives
    • 10.4.7 Teva Pharmaceutical Industries Ltd.
      • 10.4.7.1 Company overview
      • 10.4.7.2 Financial performance
      • 10.4.7.3 Product benchmarking
      • 10.4.7.4 Strategic initiatives
    • 10.4.8 F. Hoffmann-La Roche Ltd
      • 10.4.10.1 Company overview
      • 10.4.10.2 Financial performance
      • 10.4.10.3 Product benchmarking
      • 10.4.10.4 Strategic initiatives
    • 10.4.9 Novartis AG
      • 10.4.9.1 Company overview
      • 10.4.9.2 Financial performance
      • 10.4.9.3 Product benchmarking
      • 10.4.9.4 Strategic initiatives
    • 10.4.10 Novo Nordisk A/S
      • 10.4.10.1 COMPANY OVERVIEW
      • 10.4.10.2 Product benchmarking
      • 10.4.10.3 Strategic initiatives
    • 10.4.11 GlaxoSmithKline plc.
      • 10.4.11.1 Company overview
      • 10.4.11.2 Product benchmarking
      • 10.4.11.3 Strategic initiatives
    • 10.4.12 Ironwood Pharmaceuticals, Inc.
      • 10.4.12.1 Company overview
      • 10.4.12.2 Product benchmarking
      • 10.4.12.3 Strategic initiatives
    • 10.4.13 Radius Health, Inc.
      • 10.4.13.1 Company overview
      • 10.4.13.2 Cepheid
      • 10.4.13.3 Financial performance
      • 10.4.13.4 Product benchmarking
      • 10.4.13.5 Strategic initiatives
    • 10.4.14 Ipsen Pharma
      • 10.4.14.1 Company overview
      • 10.4.14.2 Cepheid
      • 10.4.14.3 Financial performance
      • 10.4.14.4 Product benchmarking
      • 10.4.14.5 Strategic initiatives

Chapter 11 Conclusion

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviation
  • Table 3 North America peptide therapeutics market estimates and forecasts, by country, 2018 - 2030 (USD Billion)
  • Table 4 North America peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Billion)
  • Table 5 North America peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Billion)
  • Table 6 North America peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Billion)
  • Table 7 North America peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Billion)
  • Table 8 North America peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Billion)
  • Table 9 U.S. peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Billion)
  • Table 10 U.S. peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Billion)
  • Table 11 U.S. peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Billion)
  • Table 12 U.S. peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Billion)
  • Table 13 U.S. peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Billion)
  • Table 14 Canada peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Billion)
  • Table 15 Canada peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Billion)
  • Table 16 Canada peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Billion)
  • Table 17 Canada peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Billion)
  • Table 18 Canada peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Billion)
  • Table 19 Europe peptide therapeutics market estimates and forecasts, by country, 2018 - 2030 (USD Billion)
  • Table 20 Europe peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Billion)
  • Table 21 Europe peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Billion)
  • Table 22 Europe peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Billion)
  • Table 23 Europe peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Billion)
  • Table 24 Europe peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Billion)
  • Table 25 UK peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Billion)
  • Table 26 UK peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Billion)
  • Table 27 UK peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Billion)
  • Table 28 UK peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Billion)
  • Table 29 UK peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Billion)
  • Table 30 Germany peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Billion)
  • Table 31 Germany peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Billion)
  • Table 32 Germany peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Billion)
  • Table 33 Germany peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Billion)
  • Table 34 Germany peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Billion)
  • Table 35 France peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Billion)
  • Table 36 France peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Billion)
  • Table 37 France peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Billion)
  • Table 38 France peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Billion)
  • Table 39 France peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Billion)
  • Table 40 Spain peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Billion)
  • Table 41 Spain peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Billion)
  • Table 42 Spain peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Billion)
  • Table 43 Spain peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Billion)
  • Table 44 Spain peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Billion)
  • Table 45 Italy peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Billion)
  • Table 46 Italy peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Billion)
  • Table 47 Italy peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Billion)
  • Table 48 Italy peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Billion)
  • Table 49 Italy peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Billion)
  • Table 50 Denmark peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Billion)
  • Table 51 Denmark peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Billion)
  • Table 52 Denmark peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Billion)
  • Table 53 Denmark peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Billion)
  • Table 54 Denmark peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Billion)
  • Table 55 Sweden peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Billion)
  • Table 56 Sweden peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Billion)
  • Table 57 Sweden peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Billion)
  • Table 58 Sweden peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Billion)
  • Table 59 Sweden peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Billion)
  • Table 60 Norway peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Billion)
  • Table 61 Norway peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Billion)
  • Table 62 Norway peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Billion)
  • Table 63 Norway peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Billion)
  • Table 64 Norway peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Billion)
  • Table 65 Asia Pacific peptide therapeutics market estimates and forecasts, by country, 2018 - 2030 (USD Billion)
  • Table 66 Asia Pacific peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Billion)
  • Table 67 Asia Pacific peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Billion)
  • Table 68 Asia Pacific peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Billion)
  • Table 69 Asia Pacific peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Billion)
  • Table 70 Asia Pacific peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Billion)
  • Table 71 Japan peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Billion)
  • Table 72 Japan peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Billion)
  • Table 73 Japan peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Billion)
  • Table 74 Japan peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Billion)
  • Table 75 Japan peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Billion)
  • Table 76 China peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Billion)
  • Table 77 China peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Billion)
  • Table 78 China peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Billion)
  • Table 79 China peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Billion)
  • Table 80 China peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Billion)
  • Table 81 India peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Billion)
  • Table 82 India peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Billion)
  • Table 83 India peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Billion)
  • Table 84 India peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Billion)
  • Table 85 India peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Billion)
  • Table 86 South Korea peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Billion)
  • Table 87 South Korea peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Billion)
  • Table 88 South Korea peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Billion)
  • Table 89 South Korea peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Billion)
  • Table 90 South Korea peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Billion)
  • Table 91 Australia peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Billion)
  • Table 92 Australia peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Billion)
  • Table 93 Australia peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Billion)
  • Table 94 Australia peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Billion)
  • Table 95 Australia peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Billion)
  • Table 96 Thailand peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Billion)
  • Table 97 Thailand peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Billion)
  • Table 98 Thailand peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Billion)
  • Table 99 Thailand peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Billion)
  • Table 100 Thailand peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Billion)
  • Table 101 Latin America peptide therapeutics market estimates and forecasts, by country, 2018 - 2030 (USD Billion)
  • Table 102 Latin America peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Billion)
  • Table 103 Latin America peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Billion)
  • Table 104 Latin America peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Billion)
  • Table 105 Latin America peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Billion)
  • Table 106 Latin America peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Billion)
  • Table 107 Brazil peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Billion)
  • Table 108 Brazil peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Billion)
  • Table 109 Brazil peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Billion)
  • Table 110 Brazil peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Billion)
  • Table 111 Brazil peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Billion)
  • Table 112 Mexico peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Billion)
  • Table 113 Mexico peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Billion)
  • Table 114 Mexico peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Billion)
  • Table 115 Mexico peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Billion)
  • Table 116 Mexico peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Billion)
  • Table 117 Argentina peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Billion)
  • Table 118 Argentina peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Billion)
  • Table 119 Argentina peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Billion)
  • Table 120 Argentina peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Billion)
  • Table 121 Argentina peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Billion)
  • Table 122 MEA peptide therapeutics market estimates and forecasts, by country, 2018 - 2030 (USD Billion)
  • Table 123 MEA peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Billion)
  • Table 124 MEA peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Billion)
  • Table 125 MEA peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Billion)
  • Table 126 MEA peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Billion)
  • Table 127 MEA peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Billion)
  • Table 128 South Africa peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Billion)
  • Table 129 South Africa peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Billion)
  • Table 130 South Africa peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Billion)
  • Table 131 South Africa peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Billion)
  • Table 132 South Africa peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Billion)
  • Table 133 UAE peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Billion)
  • Table 134 UAE peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Billion)
  • Table 135 UAE peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Billion)
  • Table 136 UAE peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Billion)
  • Table 137 UAE peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Billion)
  • Table 138 Saudi Arabia peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Billion)
  • Table 139 Saudi Arabia peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Billion)
  • Table 140 Saudi Arabia peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Billion)
  • Table 141 Saudi Arabia peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Billion)
  • Table 142 Saudi Arabia peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Billion)
  • Table 143 Kuwait peptide therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Billion)
  • Table 144 Kuwait peptide therapeutics market estimates and forecasts, by type, 2018 - 2030 (USD Billion)
  • Table 145 Kuwait peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018 - 2030 (USD Billion)
  • Table 146 Kuwait peptide therapeutics market estimates and forecasts, by route of administration, 2018 - 2030 (USD Billion)
  • Table 147 Kuwait peptide therapeutics market estimates and forecasts, by synthesis technology, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Peptide therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 QFD modelling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Application segment snapshot
  • Fig. 10 Type and type of manufacturers segment snapshot
  • Fig. 11 Route of administration and synthesis technology segment snapshot
  • Fig. 12 Competitive landscape snapshot
  • Fig. 13 Pharmaceutical market, (USD Billion)
  • Fig. 14 Market dynamics
  • Fig. 15 The most common cancers globally are listed in the table below
  • Fig. 16 Global number of new cases caused by top 11 cancer types in 2023 (in thousands)
  • Fig. 17 The figure below shows the phase of therapeutic peptides in clinical trials:
  • Fig. 18 Porter's five forces analysis
  • Fig. 19 PESTLE analysis
  • Fig. 20 Peptide therapeutics market: Application outlook and key takeaways
  • Fig. 21 Peptide therapeutics market: Application movement analysis
  • Fig. 22 Cancer market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Metabolic disorders market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Cardiovascular disorders market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Respiratory disorders market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Gastrointestinal disorders market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Infectious diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Pain market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Dermatological disorders market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Neurological disorders market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Renal disorders market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Peptide therapeutics market: Type outlook and key takeaways
  • Fig. 34 Peptide therapeutics market: Type movement analysis
  • Fig. 35 Generic market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Innovative market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Peptide therapeutics market: Type of manufacturers outlook and key takeaways
  • Fig. 38 Peptide therapeutics market: Type of manufacturers movement analysis
  • Fig. 39 In-house market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 Outsourced market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Peptide therapeutics market: Route of administration outlook and key takeaways
  • Fig. 42 Peptide therapeutics market: Route of administration movement analysis
  • Fig. 43 Parenteral route market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 Oral route market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 45 Pulmonary market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 46 Mucosal market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 47 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 48 Peptide therapeutics market: Synthesis technology outlook and key takeaways
  • Fig. 49 Peptide therapeutics market: Synthesis technology movement analysis
  • Fig. 50 Solid Phase Peptide Synthesis (SPPS) market estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 51 Liquid Phase Peptide Synthesis (LPPS) Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 52 Hybrid technology market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 53 Peptide therapeutics market revenue, by region, 2022 & 2030 (USD Million)
  • Fig. 54 Regional marketplace: Key takeaways
  • Fig. 55 Regional marketplace: Key takeaways
  • Fig. 56 North America peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 Target disease prevalence
  • Fig. 59 U.S. peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Key country dynamics
  • Fig. 61 Target disease prevalence
  • Fig. 62 Canada peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Europe peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Key country dynamics
  • Fig. 65 Target disease prevalence
  • Fig. 66 UK peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Key country dynamics
  • Fig. 68 Target disease prevalence
  • Fig. 69 Germany peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 Target disease prevalence
  • Fig. 72 France peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Key country dynamics
  • Fig. 74 Target disease prevalence
  • Fig. 75 Spain peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Key country dynamics
  • Fig. 77 Target disease prevalence
  • Fig. 78 Italy peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Key country dynamics
  • Fig. 80 Target disease prevalence
  • Fig. 81 Denmark peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 82 Key country dynamics
  • Fig. 83 Target disease prevalence
  • Fig. 84 Sweden peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 Key country dynamics
  • Fig. 86 Target disease prevalence
  • Fig. 87 Norway peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 Rest of Europe peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 89 Asia Pacific peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 Key country dynamics
  • Fig. 91 Target disease prevalence
  • Fig. 92 Japan peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 93 Key country dynamics
  • Fig. 94 Target disease prevalence
  • Fig. 95 China peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 96 Key country dynamics
  • Fig. 97 Target disease prevalence
  • Fig. 98 India peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 99 Key country dynamics
  • Fig. 100 Target disease prevalence
  • Fig. 101 Australia peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 102 Key country dynamics
  • Fig. 103 Thailand peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 104 Key country dynamics
  • Fig. 105 South Korea peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 106 Rest of Asia Pacific peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 107 Latin America peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 108 Key country dynamics
  • Fig. 109 Target disease prevalence
  • Fig. 110 Brazil peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 111 Key country dynamics
  • Fig. 112 Target disease prevalence
  • Fig. 113 Mexico peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 114 Key country dynamics
  • Fig. 115 Target disease prevalence
  • Fig. 116 Argentina peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 117 Rest of Latin America peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 118 MEA peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 119 Key country dynamics
  • Fig. 120 Target disease prevalence
  • Fig. 121 South Africa peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 122 Key country dynamics
  • Fig. 123 Target disease prevalence
  • Fig. 124 Saudi Arabia peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 125 Key country dynamics
  • Fig. 126 Target disease prevalence
  • Fig. 127 UAE peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 128 Key country dynamics
  • Fig. 129 Target disease prevalence
  • Fig. 130 Kuwait peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 131 Rest of MEA peptide therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)